Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects

Ponatinib is a BCR-ABL tyrosine kinase inhibitor (TKI) approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia in patients resistant or intolerant to prior TKIs. In vitro studies suggested that metabolism of ponatinib is partially medi...

Descripción completa

Detalles Bibliográficos
Autores principales: Narasimhan, Narayana I, Dorer, David J, Niland, Katie, Haluska, Frank, Sonnichsen, Daryl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781849/
https://www.ncbi.nlm.nih.gov/pubmed/23801357
http://dx.doi.org/10.1002/jcph.109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781849/
https://www.ncbi.nlm.nih.gov/pubmed/23801357
http://dx.doi.org/10.1002/jcph.109

Ejemplares similares